The OptiNose delivery devices have high dose reproducibility and avoid drug deposition to the lungs. In summary, the technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown the devices can provide a faster onset of action, greater effect with a lower dose and reduced side effects.
Gross profit (Q3, 2019)
Gross profit margin (Q3, 2019), %
Net income (Q3, 2019)
EBIT (Q3, 2019)
Market capitalization (6-Dec-2019)
Closing stock price (6-Dec-2019)
|USD||Q3, 2016||Q3, 2017||Q1, 2018||Q2, 2018||Q3, 2018||Q1, 2019||Q2, 2019||Q3, 2019|
Depreciation and Amortization
When was OptiNose founded?
OptiNose was founded in 2000.
Who are OptiNose key executives?
OptiNose's key executives are Peter Miller, Ramy Mahmoud and Per Djupesland.
How many employees does OptiNose have?
OptiNose has 102 employees.
What is OptiNose revenue?
Latest OptiNose annual revenue is $7.1 m.
What is OptiNose revenue per employee?
Latest OptiNose revenue per employee is $69.3 k.
Who are OptiNose competitors?
Competitors of OptiNose include Avedro, PhaseBio Pharmaceuticals and Charles River Laboratories International.
Where is OptiNose headquarters?
OptiNose headquarters is located at 1020 Stony Hill Rd #300, Morrisville.
Where are OptiNose offices?
OptiNose has offices in Morrisville, Oslo and Park.
How many offices does OptiNose have?
OptiNose has 3 offices.
Receive alerts for 300+ data fields across thousands of companies